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Introduction
The aetiology of neuronal death in neurodege-
nerative diseases is still a mystery; however, evidence of
defects in energy metabolism, excitotoxicity and oxida-
tive damage is increasingly convincing. It is likely that
there is a complex interplay among these mechanisms.
A defect in energy metabolism may lead to neuronal
depolarization, activation of N-methyl-D-aspartate
(NMDA) excitatory amino-acid receptors, and increases
in intracellular calcium, which are buffered by mito-
chondria (1, 2). 
Neurotoxicity of excitatory amino-acids con-
tributes to the pathogenesis of many forms of acute
and chronic neuronal injuries including Huntington’s
disease (HD). The NMDA class of glutamate receptors
is believed to play a prominent role in the pathogene-
sis of CNS excitotoxicity (3). Quinolinic acid (QA), a
2,3-pyridine dicarboxilic acid, has drown considerable
attention as an endogenous excitotoxic metabolite of
L-tryptophan that mediates neuronal injury through
NMDA receptor activation and subsequent elevations
of intracellular calcium, oxidative stress and lipid per-
oxidation (4, 5). Excitotoxic striatal lesions induced by
QA, a model of HD, were used to test neuroprotective
actions of nitric oxide synthase (NOS) inhibitors ’ 7-
nitroindazole (7-NI), and Nw-nitro-L-arginine methyl
ester (L-NAME). 7-NI is known to be relatively specific
for neuronal NOS (nNOS), whereas L-NAME affects
both nNOS and endotelial NOS (eNOS) (6, 7).
Jugoslov Med Biohem 2004; 23 (1) 11
UC 577,1; 61                                                                                                               ISSN 0354-3447
Jugoslov Med Biohem 23: 11–18, 2004 Originalni nau~ni rad
Original paper
EFFECTS OF VARIOUS NITRIC OXIDE SYNTHASE INHIBITORS 
ON QUINOLINIC ACID-INDUCED NEURONAL INJURY IN RATS
Ivana D. Vasiljevi}1, Marina D. Jovanovi}1, Miodrag ^oli}1, Rosa Mihajlovi}2, 
Mirjana \uki}3, Milica Ninkovi}1, @ivorad Mali~evi}1
1Institute for Medical Research, Military Medical Academy
2Institute of rehabilitation
3University School of Pharmacy, Belgrade
Summary: The aetiology of neuronal death in neurodegenerative diseases, including Huntington’s disease,
is still unknown. There could be a complex interplay among altered energy metabolism, excitotoxicity and oxida-
tive stress. Our aim was to examine the effects of intrastriatal injection of a selective inhibitor of neuronal nitric
oxide synthase, 7-nitroindazole, and a non-specific potent nitric oxide synthase inhibitor, Nw-nitro-L-arginine
methyl ester, in order to study the possible involvement of glutathione, an important antioxidant, in quinolinic
acid-induced striatal toxicity in the rat. Unilateral administration of quinolinic acid to rat striatum in a single dose
of 150 nmol/L was used as a model of Huntington’s disease. The other group of animals were pretreated with 7-
nitroindazole and Nw-nitro-L-arginine methyl ester, respectively. Control groups were treated with saline solution
and olive oil, respectively. Content of total glutathione, was increased in the ipsi- and contralateral striatum, fore-
brain cortex, basal forebrain and hippocampus in the groups treated with nitric oxid synthase inhibitors and quino-
linic acid compared to the quinolinic acid-treated animals. These results support the hypothesis that oxygen free
radicals contribute to excitotoxic neuronal injury, and also that nitric oxide synthase inhibitors could be potential
neuroprotective agents in Huntington’s disease.
Key words: Huntington’s disease; quinolinic acid; Nw-nitro-L-arginine methyl ester; 7-nitroindazole; glu-
tathione
Address for correspodence
Ivana Vasiljevi}
Institute for Medical Research
Military Medical Academy
Crnotravska 17
11000 Belgrade
E-mail: ivanav13¤yahoo.ca
There are several reports showing that overacti-
vation of NMDA receptors mediates cell death and
neurotoxicity. NMDA receptor activation increases NO
syntesis probably by increasing intracellular calcium
which binds to calmodulin, allowing it to activate NOS.
Striatal microinjection of QA is associated with neu-
ronal damage through NMDA receptor activation and
increased NOS activity (8). 
If NMDA excitotoxic process does play a role in
neuronal degeneration in HD, it is expected that the
neurons containing high densities of these receptors
are preferentially vulnerable resulting in a depletion of
NMDA receptors. The vulnerability of signaling sys-
tems to oxidative stress is influenced by intracellular
glutathione levels (GSH), indicating that cell-selective
susceptibility to inhibition of signal transduction sys-
tems by oxidative stress can arise from cellular varia-
tions in antioxidant capacity (9, 10). 
Glutathione (g-glutamylcysteinylglycine) is a na-
turally occurring tripeptide which, because of its nucle-
ophilic and reducing properties, plays a central role in
many metabolic pathways as well as in the antioxidant
defense system of most aerobic cells (11). 
In view of the above, the present study was
undertaken to examine whether the content of total
glutathione receiving intracerebral injections of QA
can be modulated with pretreatment with 7-NI and L-
NAME, respectively.
Material and Methods
Animals
The study was carried out on adult Wistar rats of
both sexes, with body weight about 250 g. Animals
were divided into four groups and were put in
macrolen cages (Erath, FRG). Animals had free access
to food and water. Average microclimate conditions
were as follows: room temperature  23 ± 2 °C, air hu-
midity 55 ± 10%, air was conditioned by 10 to 50
exchanges per hour, and light regimen was in a cycle
of 12 hours from 7 to 19 hours. These animals were
anesthetized by pentobarbital sodium i.p. in a dose of
0.0405 g/kg b.w., and were placed in a stereotaxic
frame. 
Experimental procedure
The rats were divided into seven groups (accor-
ding to drug treatment) and each group was com-
posed of 8 animals. The first group received an unila-
teral injection of QA (Aldrich Chemical Company, Inc.)
in a single dose of 250.7 mg (dissolved in H2O) using
stereotaxic instrument for small animals as coordinate
for striatum (8.4; 2.4; 5.0 mm). The second and third
groups were treated with 7-NI (Sigma Chemical Co.
U.S.A.; 1×10-4g dissolved in olive oil)+QA and 7-
NI+saline solution (ss). The fourth and fifth groups
were treated with L-NAME (Sigma Chemical Co.
U.S.A.; 1×100’ 4 g dissolved in saline solution)+QA
and L-NAME+saline solution (ss). 7-NI was immedi-
ately used before neurotoxin in contrast to L-NAME
that was used thirty minutes before QA. The sixth
group received the same volume but only 0.154
mmol/L of saline solution and served as a control-
sham-operated (Kss). Finally, the seventh group
received the same volume of olive oil and also served
as a control (Koo). In all treated animals the injected
intracerebral volume was 10 × 10’6 mL. 
All animals were killed by decapitation 7 days
after the treatment and the brains immediately
removed. Ipsi- and contralateral striatum, forebrain
cortex, basal forebrain as well as hippocampus from
individual animals were quickly isolated and homoge-
nized in ice-cold buffer containing 0.25 mol of
sucrose, 0.1 mmol of EDTA, 50 mmol of K-Na phos-
phate buffer, pH=7.2. Homogenates were centrifuged
twice at 1580 g for 15 min at 4 °C. The supernatant
obtained by this procedure was then frozen and stored
at ’70 °C (12).
Content of total glutathione measurement
A prepared crude mitochondrial fraction of stria-
tum, forebrain cortex, basal forebrain and hippocam-
pus was used for the appropriate biochemical analysis.
Content of total glutathione (GSH+1/2 GSSG, in GSH
equivalents) was determined with DTNB-GSSG reduc-
tase recycling assay. The rate of formation of 5-thio-2-
nitrobenzoic acid (TNB), which is proportional to the
total GSH concentration, was followed spectrophoto-
metrically at 412 nm (13).
Protein measurement
The content of protein in the rat brain homo-
genates (ipsi- and contralateral striatum, forebrain cor-
tex, basal forebrain and hippocampus) was measured
by the method of Lowry et al. using bovine serum
albumin (Sigma) as standard (14). 
Data presentation and analysis
All experiments were done in n=8. Data are
expressed as means ± SD. Differences among groups
were examined using Student’s independent t-test.
Statistical significance was accepted at p<0.05.
Results
Content of total glutathione in the rat striatum
Results presented in Figure 1 show the content
of total glutathione (nmol GSH/mg prot.) in ipsi- and
contralateral striatum homogenates. QA injection re-
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sults show a general reduction in glutathione produc-
tion in ipsi- and contralateral striatum compared to the
Kss animals (ipsilateral striatum = 175.819 ± 29.181;
contralateral striatum = 139.272 ± 25.169). There
was no statistically significant difference in content of
total glutathione obtained from each hemisphere,
although injection site was in ipsilateral striatum. 7-NI
treatment followed by QA clearly revealed the higher
levels of glutathione in ipsi- and contralateral brain
structures compared to Kss group (ipsilateral striatum
= 175.819 ± 29.181; contralateral striatum =
139.272 ± 25.169). L-NAME+QA, L-NAME+ ss and
7-NI+ ss treatment showed a significant increase in
glutathione levels in contralateral striatum compared
to Kss group (contralateral striatum = 139.272 ±
25.169). Content of total glutathione was significantly
increased in ipsi- and contralateral striatum of NOS
inhibitors-treated animals as well as in Kss group com-
pared to QA-treated animals (ipsilateral striatum =
101.025 ± 23.352; contralateral striatum = 106.127 ±
19.346). Glutathione levels evidently decreased in ipsi-
and contralateral striatum of Koo animals compared
to Kss group (ipsilateral striatum = 175.819 ± 29.181;
contralateral striatum = 139.272 ± 25.169). Finally,
content of total glutathione was increased in ipsilateral
striatum of Koo group compared to QA-treated ani-
mals (ipsilateral striatum = 101.025 ± 23.352). 
Content of total glutathione 
in the rat forebrain cortex
The effect of different intrastriatal drug injections
on the content of total glutathione in forebrain cortex
is shown in Figure 2. The effect of 7-NI+QA, 7-NI+ ss
and L-NAME+QA on glutathione levels in ipsi- and
contralateral forebrain cortex was in a significant
increase compared to Kss animals (ipsilateral fore-
brain cortex = 146.083 ± 26.56; contralateral fore-
brain cortex = 126.415 ± 21.132). The content of total
glutathione was decreased in ipsi- and contralateral
forebrain cortex in Koo animals compared with Kss
group (ipsilateral forebrain cortex = 146.083 ± 26.56;
contralateral forebrain cortex = 126.415 ± 21.132). L-
NAME+QA, 7-NI+QA and 7-NI+ ss treatment in ipsi-
and contralateral forebrain cortex showed a significant
increase in glutathione levels compared to QA-treated
animals (ipsilateral forebrain cortex = 116.916 ±
21.639; contralateral forebrain cortex = 129.767 ±
20.594). There was not statistically significant differen-
ce in content of total glutathione obtained from each
hemisphere. 
Content of total glutathione 
in the rat basal forebrain
Results obtained from this brain structure (Figure
3) were similar to the previous related to striatum.
Content of total glutathione was mutually depleted in
ipsi- and contralateral basal forebrain of QA-treated
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Figure 1. Content of total glutathione in the ipsi- and contralateral striatum of QA- and NOS inhibitors-treated Wistar rats. 
(Si, Sc = striatum ipsi-, contralateral). Values are given as nmol GSH/mg prot. 
Mean ± S.D. * ’ Significance of corresponding values of Kss control group. 
# ’ Significance of corresponding values of QA-treated group. (Student’s t-test, p < 0.05).   
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Figure 2. Content of total glutathione in the ipsi- and contralateral forebrain cortex of QA- and NOS inhibitors-treated 
Wistar rats. (Cxi, Cxc = forebrain cortex ipsi-, contralateral). Values are given as nmol GSH/mg prot. 
Mean ± S.D. * ’ Significance of corresponding values of Kss control group. 
# ’ Significance of corresponding values of QA-treated group. (Student’s t-test, p < 0.05). 
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Figure 3. Content of total glutathione in the ipsi- and contralateral basal forebrain of QA- and NOS inhibitors-treated 
Wistar rats. (BFi, BFc = basal forebrain ipsi-, contralateral). Values are given as nmol GSH/mg prot. 
Mean ± S.D. * ’ Significance of corresponding values of Kss control group. 
# ’ Significance of corresponding values of QA-treated group. (Student’s t-test, p < 0.05). 
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animals compared to Kss group (ipsilateral basal fore-
brain= 177.048± 21.712; contralateral basal forebrain
= 193.665 ± 42.253). The effect of L-NAME+QA, 7-
NI+QA and Koo control group in ipsi- and contrala-
teral basal forebrain and 7-NI+ ss in ipsilateral basal
forebrain on glutathione levels showed a significant
increase compared to Kss group (ipsilateral basal fore-
brain = 177.048 ± 21.712; contralateral basal fore-
brain = 193.665 ± 42.253). There was a significant
increase in glutathione levels after NOS inhibitors-
treated animals and Kss animals in ipsi- and con-
tralateral basal forebrain, as well as in contralateral
basal forebrain of Koo animals compared to QA-trea-
ted group (ipsilateral basal forebrain = 134.755 ±
27.829; contralateral basal forebrain = 124.592 ±
29.944). There was no statistically significant differ-
ence in content of total glutathione obtained from
each hemisphere. 
Content of total glutathione
in the rat hippocampus
The effect of different intrastriatal drug injections
on glutathione levels in hippocampus is shown in
Figure 4. The effect of QA-treated group and Koo
group on content of total glutathione showed a signi-
ficant reduction compared to Kss animals (ipsilateral
hippocampus=188.155 ± 20.358; contralateral hip-
pocampus=177. 581 ± 20.681). L-NAME+QA sho-
wed a significant increase in glutathione levels both in
ipsi- and contralateral side compared to Kss animals
(ipsilateral hippocampus = 188.155 ± 20.358; con-
tralateral hippocampus = 177.581 ± 20.681). Content
of total glutathione was significantly increased in the
ipsi- and contralateral hippocampus of NOS inhibi-
tors-treated animals, as well as in Kss group compa-
red to QA-tre-ated animals (ipsilateral hippocam-
pus=122.555 ± 20.733; contralateral hippocam-
pus=122.31 ± 25.855). 
Discussion
Bioenergetic defects and oxidative stress could
be critical links in excitotoxic mechanisms of neuronal
death. Imbalance between production and removal of
free radicals would be abrasive for a neuron (15).
Increase in intracellular levels of reactive oxygen
species (ROS), frequently referred to as oxidative
stress, is a potentially toxic insult which, if not coun-
teracted, will lead to membrane dysfunction, DNA da-
mage and inactivation of proteins. Glutathione-associ-
ated metabolism is a major mechanism of cellular pro-
tection against agents generated in oxidative stress.
Glutathione tripeptide is central in a complex multi-
faced detoxification system, where there is a substan-
tial inter-dependence among separate component
members. Glutathione provides a cell with multiple
defences not only against ROS but also against their
toxic products (16). A reduced form of this nonprotein
thiol is the main endogenous antioxidative compound
responsible for control of redox state in the cell as well
as in the extracellular space (17). 
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Figure 4. Content of total glutathione in the ipsi- and contralateral hippocampus of QA- and NOS inhibitors-treated 
Wistar rats. (Hi, Hc = hippocampus ipsi-, contralateral). Values are given as nmol GSH/mg prot. 
Mean ± S.D. * ’ Significance of corresponding values of Kss control group. 
# ’ Significance of corresponding values of QA-treated group. (Student’s t-test, p < 0.05).
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QA may lead to the generation of free radicals
since it can induce lipid peroxidation in the brain. The-
re could be a connection between the found decrease
in GSH level in ipsi- and contralateral striatum of QA-
treated animals and this secondary oxidative stress
(Figure 1). Hydrogen peroxide, formed in the respira-
tory chain among the other toxic oxygen forms, if not
reduced (process dependent on GSH-redox cycle) can
induce a generation of aggressive hydroxyl radicals
and consequent membrane lipid peroxidation. Oxi-
dation of glutathione could disrupt Ca2+ homeostasis
through the oxidation of protein thiol groups of the
inner mitochondrial membrane leading to increase of
free cytosolic Ca2+ which initiates many potentially to-
xic reactions dangerous for cell integrity (18). Once ac-
tivated the chain of free radical reactions has a chara-
cteristic spread and propagation of cascade reactions,
respectively, with amplifying the initial effects. It means
that chain reactions, spread in space and time, lead to
the neuronal cell death. These observations are sup-
ported by the observed involvement of contralateral
striatum, basal forebrain and hippocampus, which are
spaciously relatively distinct from ipsilateral striatum,
the place of direct neurotoxine use (Figures 1, 3, 4). 
QA kills hippocampal neurons via an oxidative
pathway associated with total glutathione depletion.
NMDA receptor activation increases NO synthesis
probably by increasing intracellular calcium which
binds to calmodulin, allowing it to activate NOS (19).
Striatal use of QA is associated with neuronal damage
through NMDA receptor activation, increased NOS
activity and decrease in the total glutathione content.
Decreased total glutathione content in the basal fore-
brain and hippocampus, the structures distant from
ipsilateral treated striatum, could indicate a spatial
propagation of oxidative stress, not only in the selec-
tively vulnerable striatal GABA-ergic neurons but in the
structures included in the motor and cognitive loops of
basal ganglia (Figures 3, 4). 
NOS inhibitors were proposed as the candidates
for the treatment of neurodegenerative disease (20). 7-
NI and l-NAME differentially protect striatal and corti-
cal projection neurons and interneurons against the
injection of NMDA receptor agonist, QA. 
Selective inhibition of nNOS by pharmacological
agents such as 7-NI reduces lesion, reinforcing the
idea that nNOS contributes to excitotoxic neuronal
damage (21). In the present study we report on that 7-
NI increased the content of total glutathione in ipsi-
and contralateral striatum, forebrain cortex, basal fore-
brain and hippocampus compared to QA-treated ani-
mals. Moreover, the less selective nNOS inhibitor L-
NAME altered not the content of total glutathione in
ipsi- and contralateral forebrain cortex when the L-
NAME+saline solution were acutely used to the rat
striatum (Figure 2). Excessive NOS dependent on NO
release during high levels of NMDA receptor stimula-
tion results in production of toxic hydroxyl radicals and
nitrogen dioxide. In the present report 7-NI was effec-
tive in elevation of total glutathione content in the fore-
brain cortex, while L-NAME was ineffective. One possi-
ble explanation of these results is the relative specifici-
ty of the two compounds in nNOS. While the neuro-
protective properties of 7-NI are likely an antagonism
of nNOS, the trend toward increased lesion with L-
NAME may have resulted from nonspecific antago-
nism of eNOS. The relative effectiveness of NOS
antagonists as neuroprotectants may in part depend
on their relative specificity of the neuronal form of
NOS.
According to the assumption that L-NAME, a
non-specific potent NOS inhibitor, protects neurons
from reactive oxigen species, we found increased total
glutathione content in ipsi- and contralateral striatum,
basal forebrain and hippocampus. These effects of L-
NAME could be due to the influence on the cellular
antioxidant defence system, stimulated cellular repair
system or decreased slow excitotoxicity effects and
their spatial and temporal propagation (22). L-NAME
indirectly regulates the metabolism of glutathione, a
small reduced peptide, involved in the detoxification of
free radicals (23). Content of total glutathione was
increased in ipsi- and contralateral striatum, basal
forebrain and hippocampus of L-NAME+QA and L-
NAME+saline solution treated animals, as well as in
ipsi- and contralateral forebrain cortex of L-NAME+
QA treated animals compared to QA-treated group.
This indicates that the main protective influence of
L-NAME includes its direct and indirect participation in
glutathione metabolism and its effects on cellular
homeostasis. 
The content of total glutathione, as a indicator of
reduced cell atmosphere, was mutually depleted in
ipsilateral striatum and contralateral basal forebrain of
olive oil-control group (Koo) compared to QA-treated
animals (Figures 1, 3). Synthesis of GSH is closely
related to the cell redox state represented by
NAD(P)H/NAD(P) ratio that is dependent on glucose-
6-phosphate dehydrogenase activity. GSH depletion
could contribute to neuronal apoptosis in HD through
oxidative stress and mitochondrial dysfunction (24). 
The age-related onset and progressive course of
HD may be due to a cycling process between impaired
energy metabolism and oxidative stress. The deleteri-
ous networks in the brain of HD are formed on the
basis of the intimate interactions among the key path-
ogenic factors, including oxidative damage, aberrant
calcium homeostasis and metabolic compromise.
The present results indicate that striatal lesions
induced changes in the functional activity of basal
ganglionic nuclei and NOS inhibitors partly reversed
the alterations in the functional state of the basal gan-
glia circuitry. In our study the in vivo cytoprotective
effects of NOS inhibitors against striatal excitotoxic
lesions suggest that both 7-NI and l-NAME could be
used as potential neuroprotective agents in HD, which
has been suggested to involve excitotoxicity.
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Kratak sadr`aj: Etiologija selektivnog umiranja neurona u neurodegenerativnim bolestima je nepoznata,
iako postoje dokazi o defektu energetskog metabolizma, ekscitotoksi~nosti i oksidativnom o{te}enju. Verovatno
je da klju~nu ulogu ima kompleksna interakcija izme|u ovih mehanizama. Cilj ovog rada bio je da se ispitaju efek-
ti intrastrijatne primene selektivnog inhibitora neuronske azot oksid sintaze, 7-nitroindazola, kao i nespecifi~nog
inhibitora azot oksid sintaze, Nw-nitro-l-arginin metil estra, zbog mogu}e uklju~enosti glutationa, klju~nog antiok-
sidansa, u toksi~nost strijatuma izazvanu hinolinskom kiselinom, kod pacova. Unilateralna aplikacija hinolinske
kiseline, u strijatum pacova u pojedina~noj dozi od 150 nmol/L kori{}ena je kao model Hantingtonove bolesti.
Druge grupe `ivotinja tretirane su 7-nitroindazolom, odnosno Nw-nitro-l-arginin metil estrom. Kontrolne grupe
dobijale su fiziolo{ki rastvor, odnosno maslinovo ulje. Sadr`aj ukupnog glutationa je pove}an u ipsi- i kontralate-
ralnom strijatumu, kori prednjeg mozga, bazalnom prednjem mozgu i hipokampusu grupa `ivotinja koje su pored
hinolinske kiseline primile i odgovaraju}i inhibitor neuronske azot oksid sintaze, u pore|enju sa grupom tretira-
nom samo neurotoksinom. Ovi podaci pokazuju da kiseoni~ni slobodni radikali u~estvuju u ekscitotoksi~nom
o{te}enju neurona, kao i da inhibitori azot oksid sintaze mogu biti potencijalni neuroprotektivni agensi u
Hantingtonovoj bolesti.
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